MOPOPManual of Patent Office Practice (Canadian Intellectual Property Office)
References in periodicals archive ?
79) As a result, genetic technologies remain patentable in Canada, but there is great ambiguity about the extent of their patentability given the conflicting SCC decisions and an unrevised MOPOP.
The MOPOP is currently under review to incorporate the Supreme Court of Canada's decision in Harvard College v.
While the MOPOP, supra note 2, does not specifically address patents for second medical indications, the practice of the Canadian Patent Office is evident in the granting of patents for second medical indications, as occurred in the case of Zoloft [TM].